Irritable bowel syndrome

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. It is characterized by symptoms of abdominal pain, bloating, and abnormal bowel movements, such as diarrhea or constipation. In IBS, there appears to be no organic substance or biochemical abnormality that can explain the symptoms. IBS can be classified into categories: constipation predominant IBS (IBS-C), diarrhea predominant IBS (IBS-D), mixed IBS (IBS-M), and un-subtyped IBS. Anticholinergic drugs, 5-HT3 receptor antagonist, high molecular weight polymers (polycarbophil calcium), gastrointestinal motility regulators, probiotics preparations, and laxatives are used in the treatment of IBS. However, they are not uniformly effective. Several studies of patients with IBS suggest that this disorder aggregates in families, and thus, appears potentially heritable. It has been reported that familial GUCY2C diarrhoea syndrome shares clinical characteristics with IBS-D.

Digestive system disease

GUCY2C [HSA:2984] [KO:K12320]

Dicyclomine hydrochloride [DR:D00717]
Alosetron hydrochloride [DR:D02829]
Hyoscyamine sulfate [DR:D00719]
Chlordiazepoxide hydrochloride and clidinium bromide [DR:D10247]
Lubiprostone [DR:D04790]
Linaclotide [DR:D09355]
Plecanatide [DR:D09948]
Tenapanor hydrochloride [DR:D11653]
Eluxadoline [DR:D10403]

PMID:21333900

Saito YA

The role of genetics in IBS.

Gastroenterol Clin North Am 40:45-67 (2011)
DOI:10.1016/j.gtc.2010.12.011

PMID:27372289

Shah SL, Lacy BE

Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence.

Curr Gastroenterol Rep 18:41 (2016)
DOI:10.1007/s11894-016-0517-x

PMID:27338166

von Volkmann HL, Nylund K, Tronstad RR, Hovdenak N, Hausken T, Fiskerstrand T, Gilja OH

An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel.

Scand J Gastroenterol 1-8 (2016)
DOI:10.1080/00365521.2016.1200139

PMID:11488427 (drug)

Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K

Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.

Jpn J Pharmacol 86:281-8 (2001)
DOI:10.1254/jjp.86.281

PMID:22837880 (drug)

Fukushima Y, Suzuki H, Matsuzaki J, Kiyosue A, Hibi T

Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.

J Neurogastroenterol Motil 18:317-23 (2012)
DOI:10.5056/jnm.2012.18.3.317